

# Yoshihiko Ooka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4835349/publications.pdf>

Version: 2024-02-01

68  
papers

1,606  
citations

304368

22  
h-index

315357

38  
g-index

69  
all docs

69  
docs citations

69  
times ranked

2612  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma. PLoS ONE, 2022, 17, e0261619.	1.1	4
2	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 48-60.	4.2	25
3	A case of hepatocellular carcinoma followed by asynchronous metastasis to the lung and thoracic spine following radical ablation treatment. Acta Hepatologica Japonica, 2021, 62, 25-32.	0.0	1
4	Vascular Roadmap Generation by Registration and Blending of Multiple Enhanced X-ray Angiograms. IEEE Access, 2021, 9, 36356-36367.	2.6	1
5	The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Scientific Reports, 2021, 11, 5303.	1.6	20
6	Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 473-484.	4.2	28
7	Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Investigational New Drugs, 2020, 38, 172-180.	1.2	57
8	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2020, 5, 167-228.	3.7	320
9	Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 583-595.	4.2	71
10	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer, 2020, 9, 596-612.	4.2	10
11	Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 382-396.	4.2	54
12	Long-term administration of Tolvaptan to patients with decompensated cirrhosis. International Journal of Medical Sciences, 2020, 17, 874-880.	1.1	5
13	Weight-based dosing of lenvatinib for advanced hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2020, 9, 253-254.	0.7	1
14	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clinical and Molecular Hepatology, 2020, 26, 155-162.	4.5	44
15	Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. BMC Cancer, 2019, 19, 1088.	1.1	28
16	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatology International, 2019, 13, 649-661.	1.9	72
17	Genome-Wide Mapping of Bivalent Histone Modifications in Hepatic Stem/Progenitor Cells. Stem Cells International, 2019, 2019, 1-10.	1.2	5
18	A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology, 2018, 67, 575-585.	3.6	57

#	ARTICLE	IF	CITATIONS
19	Respiratory-synchronized digital subtraction angiography based on a respiratory phase matching method. <i>Signal, Image and Video Processing</i> , 2018, 12, 539-547.	1.7	1
20	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. <i>Investigational New Drugs</i> , 2018, 36, 332-339.	1.2	52
21	Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. <i>Hepatology International</i> , 2018, 12, 523-530.	1.9	24
22	Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. <i>Oncotarget</i> , 2018, 9, 5509-5513.	0.8	5
23	Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. <i>Oncotarget</i> , 2018, 9, 11631-11637.	0.8	10
24	Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events. <i>Oncotarget</i> , 2018, 9, 16263-16270.	0.8	5
25	Risk factors of ineffective drainage in uncovered self-expandable metal stenting for unresectable malignant hilar biliary strictures. <i>Oncotarget</i> , 2018, 9, 28185-28194.	0.8	6
26	Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 21560-21568.	0.8	6
27	Successful Treatment of Hepatocellular Carcinoma Complicated by Fanconi Anemia. <i>Case Reports in Gastroenterology</i> , 2017, 11, 29-35.	0.3	0
28	Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. <i>European Journal of Cancer</i> , 2017, 86, 349-357.	1.3	82
29	Presence of non-hypervascular hypointense nodules on Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 908-915.	1.4	15
30	Hepatocellular carcinoma complicated by acute promyelocytic leukemia: a case report. <i>Acta Hepatologica Japonica</i> , 2017, 58, 176-182.	0.0	0
31	A case of arteriovenous fistula due to a ruptured hepatic aneurysm during sorafenib therapy for hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2017, 58, 605-610.	0.0	1
32	Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. <i>Biology</i> , 2017, 6, 30.	1.3	11
33	Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. <i>International Journal of Molecular Sciences</i> , 2017, 18, 906.	1.8	28
34	Suspected heparin-induced thrombocytopenia in patients with advanced hepatocellular carcinoma following hepatic arterial infusion chemotherapy. <i>Acta Hepatologica Japonica</i> , 2017, 58, 647-653.	0.0	2
35	Impact of Radiofrequency Ablation-Induced Glisson's Capsule-Associated Complications in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2017, 12, e0170153.	1.1	15
36	Henoch-Schönlein Purpura Complicated by Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2017, 56, 3041-3045.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 21315-21326.	0.8	39
38	Clinical outcomes of endoscopic ultrasound-guided ethanol injection for hepatocellular carcinoma in the caudate lobe. <i>Endoscopy International Open</i> , 2016, 04, E1111-E1115.	0.9	12
39	A case of hepatocellular carcinoma with spontaneous regression of a tumor thrombus invading the main portal trunk. <i>Acta Hepatologica Japonica</i> , 2016, 57, 178-185.	0.0	2
40	Successful treatment of two patients with hepatocellular carcinoma exhibiting severe pancytopenia caused by aplastic anemia. <i>Acta Hepatologica Japonica</i> , 2016, 57, 557-560.	0.0	1
41	Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. <i>Investigational New Drugs</i> , 2016, 34, 255-260.	1.2	40
42	Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0161303.	1.1	7
43	Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0163119.	1.1	6
44	Dexamethasone for the prevention of transcatheter arterial chemoembolization-induced fever, nausea, vomiting, and anorexia in patients with hepatocellular carcinoma: A randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 4071-4071.	0.8	3
45	Tolvaptan treatment for patients with decompensated cirrhosis and advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, E161-2.	1.8	3
46	A case of hepatocellular carcinoma with disappearance of lymph node metastasis after sorafenib administration. <i>Acta Hepatologica Japonica</i> , 2015, 56, 469-476.	0.0	1
47	Two patients with hepatic mucosa-associated lymphoid tissue lymphoma resembling hypervascular hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2015, 56, 536-539.	0.0	1
48	Three hepatocellular carcinoma patients with pleural effusion successfully treated by pleurodesis with a view to palliative medicine. <i>Acta Hepatologica Japonica</i> , 2015, 56, 213-216.	0.0	0
49	Successful treatment of three elderly patients aged ≥90 years with hepatocellular carcinoma. <i>Acta Hepatologica Japonica</i> , 2015, 56, 628-631.	0.0	1
50	A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>PLoS ONE</i> , 2015, 10, e0125244.	1.1	34
51	Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2015, 33, 1257-1262.	1.2	75
52	Fatal Diaphragmatic Hernia following Radiofrequency Ablation for Hepatocellular Carcinoma: A Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2015, 8, 238-245.	0.3	18
53	Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1197-1204.	1.4	36
54	Natural history of large regenerative nodules and dysplastic nodules in liver cirrhosis: 28-year follow-up study. <i>Hepatology International</i> , 2015, 9, 330-336.	1.9	44

#	ARTICLE	IF	CITATIONS
55	Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?. World Journal of Gastroenterology, 2015, 21, 8888.	1.4	3
56	Biological features and biomarkers in hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 2020.	0.8	12
57	Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma. Anticancer Research, 2015, 35, 549-54.	0.5	6
58	Effect of Previous Interferon-based Therapy on Recurrence after Curative Treatment of Hepatitis C Virus-related Hepatocellular Carcinoma. International Journal of Medical Sciences, 2014, 11, 707-712.	1.1	21
59	Partial Splenic Embolization with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Accompanied by Thrombocytopenia. BioMed Research International, 2014, 2014, 1-6.	0.9	4
60	Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners. PLoS ONE, 2014, 9, e84807.	1.1	70
61	IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. International Journal of Hepatology, 2014, 2014, 1-6.	0.4	9
62	A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. Investigational New Drugs, 2014, 32, 723-728.	1.2	11
63	Successful Interventional Treatment for Arterioportal Fistula Caused by Radiofrequency Ablation for Hepatocellular Carcinoma. Case Reports in Oncology, 2014, 7, 833-839.	0.3	10
64	Intracranial Metastasis in a Patient with Hepatocellular Carcinoma and Gastric Cancer. Case Reports in Oncology, 2014, 7, 199-203.	0.3	5
65	A phase I/II study of capecitabine combined with peginterferon alfa-2a in sorafenib-refractory advanced hepatocellular carcinoma patients.. Journal of Clinical Oncology, 2014, 32, 346-346.	0.8	0
66	Efficacy of transarterial chemoembolization targeting portal vein tumor thrombus in patients with hepatocellular carcinoma. Anticancer Research, 2014, 34, 4231-7.	0.5	21
67	Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. Hepatology International, 2013, 7, 703-713.	1.9	7
68	Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magnetic Resonance Imaging, 2013, 31, 748-754.	1.0	34